Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0986 | manidipine

Molecular Formula C35H38N4O6
Molecular Weight 610.7
Structure
State solid
Route of elimination Manidipine is eliminated through extensive metabolism. 63% is eliminated in the feces and 31% in the urine as metabolites [A7845].
Protein binding Manidipine is 99% bound to human plasma proteins [A7845].
Half life The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.
Absorption The median Tmax is 1.5 h [A7845]. Administration with food produces an 1.3-1.6-fold increase in Cmax but no change in Tmax. Manidipine does not accumulate significantly with multiple doses.

C

C09BB12 Delapril and manidipine


[C09BB] ACE inhibitors and calcium channel blockers


[C09B] ACE INHIBITORS, COMBINATIONS


[C09] AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM


[C] Cardiovascular system

C08CA11 Manidipine


[C08CA] Dihydropyridine derivatives


[C08C] SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS


[C08] CALCIUM CHANNEL BLOCKERS


[C] Cardiovascular system

Toxicity Dose Time Species Model Method Action Positive criterion Reference
MEMBRANE POTENTIAL 12.15±6.82 human qHTS-HepG2 MMP assay decrease IC50 163
MEMBRANE POTENTIAL 27.48 human HepG2 MMP assay decrease IC50 163
MEMBRANE POTENTIAL 20.91±5.06 rat hepatocytes MMP assay decrease IC50 163

Pictogram Signal Statements Precautionary Statement Codes
Danger

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.


H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]


 P264, P270, P301+P310, P321, P330, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Organism Test type Route Dose (normalized dose) Effect Source
mouse LD50 oral 171mg/kg (171mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 17(Suppl,
rat LD50 subcutaneous 199mg/kg (199mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 17(Suppl,
mouse LD50 subcutaneous 340mg/kg (340mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 17(Suppl,
rat LD50 intraperitoneal 49mg/kg (49mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 17(Suppl,
rat LD50 oral 156mg/kg (156mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 17(Suppl,
mouse LD50 intraperitoneal 62mg/kg (62mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 17(Suppl,


  • 092M684 120092-68-4 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid O5-[2-[4-(diphenylmethyl)-1-piperazinyl]ethyl] ester O3-methyl ester
    2-(4-Diphenylmethyl-1-piperazinyl)ethyl methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate 2-[4-(diphenylmethyl)piperazin-1-yl]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(4-(diphenylmethyl)-1-piperazinyl)ethyl methyl ester
    3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-[2-[4-(diphenylmethyl)-1-piperazinyl]ethyl] 5-methyl ester 3,5-Pyridinedicarboxylicacid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,3-[2-[4-(diphenylmethyl)-1-piperazinyl]ethyl] 5-methyl ester, hydrochloride(1:2) 3-(2-(4-Benzhydrylpiperazin-1-yl)ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-
    3-(2-(4-Benzhydrylpiperazin-1-yl)ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 3-{2-[4-(diphenylmethyl)piperazin-1-yl]ethyl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 4CH-007438
    5-O-[2-(4-benzhydrylpiperazin-1-yl)ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 89226-50-6 89226-75-5
    A804429 AB0012678 AB01274741-01
    AB01274741-02 AB01274741-03 AB01274741_04
    AB01274741_05 AB2000589 ACMC-20conv
    AK-72917 AKOS003589070 AKOS016842350
    ANEBWFXPVPTEET-UHFFFAOYSA-N Artedil Artedil (TN)
    BCP21717 BCP9000893 BCP9000919
    BDBM50227969 BR-72917 BRD-A90695733-001-01-7
    C-23346 C35H38N4O6 CCG-213069
    CHEBI:135849 CHEMBL312176 CS-2523
    CTK5G2647 CV 4093 CV 4093;CV-4093;CV4093;Franidipine;89226-50-6
    D08155 DB-041526 DB09238
    DS-1275 DTXSID2043745 FT-0631098
    FT-0670936 Franidipine HMS2089K12
    HMS3264H11 HMS3656C06 HY-B0419
    Iperten KS-00000GIQ LS-130875
    MCULE-7098869865 MLS004774156 MLS006011791
    Manidipine (INN) Manidipine (Manyper) Manidipine 6300
    Manidipine 6300 [INN] Manidipine HCl Manidipine [INN]
    Manidipine pound>>CV-4093 pound>>Franidipine pound>>( inverted exclamation markA)-Manidipine Manidipine(Manyper) NCGC00167493-01
    NCGC00167493-02 NCGC00167493-03 NCGC00167493-04
    O5-[2-[4-(diphenylmethyl)piperazin-1-yl]ethyl] O3-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Q921133 S-6064
    SC-25949 SCHEMBL49368 SMR003500793
    SR-05000002134 SR-05000002134-1 ST24028270
    STK635322 SW219347-1 TR-038262
    VA11233 VP13803 Z5288
    manidipine s2481

    DrugBank Name manidipine
    DrugBank DB09238
    CAS Number 120092-68-4, 126451-47-6, 133082-19-6, 89226-50-6, 89226-75-5, 94849-74-8
    PubChem Compound 4008
    KEGG Drug D08155
    ChEBI 135849